Literature DB >> 15544617

TSH receptor-adenovirus-induced Graves' hyperthyroidism is attenuated in both interferon-gamma and interleukin-4 knockout mice; implications for the Th1/Th2 paradigm.

Y Nagayama1, O Saitoh, S M McLachlan, B Rapoport, H Kano, Y Kumazawa.   

Abstract

The role of the Th1/Th2 balance in the pathogenesis of murine Graves' hyperthyroidism is controversial. In BALB/c mice injected with adenovirus expressing TSH receptor (TSHR-adeno model), we found that suppression of TSHR-specific Th1 immune responses by exogenous interleukin-4 (IL-4), alpha-galactosylceramide or helminth (Schistosoma mansoni) infection was associated with inhibition of hyperthyroidism, indicating the critical role for Th1 cytokines. In contrast, BALB/c IL-4 knockout (KO), but not interferon-gamma (IFN-gamma) KO mice failed to develop Graves' hyperthyroidism when injected with TSHR-expressing M12 B lymphoma cells (TSHR-M12 model), suggesting the importance of Th2 cytokine IL-4. To reconcile differences in these two models, we used IL-4 KO and IFN-gamma KO BALB/c mice in the TSHR-adeno model. Unlike wild-type (wt) BALB/c mice in which 60% developed hyperthyroidism, only 13 and 7% of IL-4 KO and IFN-gamma KO mice, respectively, became hyperthyroid. Thyroid stimulating antibodies were positive in most hyperthyroid mice. TSHR antibody titres determined by TSH binding inhibition and ELISA were comparable in all three groups. IgG1 and IgG2a TSHR antibody titres were similar in IFN-gamma KO and wt mice, whereas IgG1 TSHR antibody titres and TSHR-specific splenocyte IFN-gamma secretion were lower in IL-4 KO than in IFN-gamma KO and wt mice, respectively. Our results clearly implicate both IFN-gamma and IL-4 in development of hyperthyroidism in the TSHR-adeno model. These data, together with the previous report, also indicate different cytokine requirements in these two Graves' models, with IFN-gamma being more important in the TSHR-adeno than the TSHR-M12 model. Moreover, our previous and present observations indicate a difference in the role of exogenous versus endogenous IL-4 in TSHR-adenovirus induced Graves' hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15544617      PMCID: PMC1809247          DOI: 10.1111/j.1365-2249.2004.02641.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

Review 1.  Towards a comprehensive view of immunoglobulin class switching.

Authors:  C M Snapper; J J Mond
Journal:  Immunol Today       Date:  1993-01

2.  Gamma-interferon is one of several direct B cell-maturing lymphokines.

Authors:  C L Sidman; J D Marshall; L D Shultz; P W Gray; H M Johnson
Journal:  Nature       Date:  1984 Jun 28-Jul 4       Impact factor: 49.962

3.  Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine.

Authors:  Yuji Nagayama; Hiroyuki Mizuguchi; Takao Hayakawa; Masami Niwa; Sandra M McLachlan; Basil Rapoport
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

4.  Absence of IL-4, and not suppression of the Th2 response, prevents development of experimental autoimmune Graves' disease.

Authors:  Rukiye-Nazan E Dogan; Chenthamarakshan Vasu; Mark J Holterman; Bellur S Prabhakar
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

5.  Signal transducer and activator of transcription (Stat)-6-dependent, but not Stat4-dependent, immunity is required for the development of autoimmunity in Graves' hyperthyroidism.

Authors:  Kimberly J Land; Jennifer S Moll; Mark H Kaplan; Gattadahalli S Seetharamaiah
Journal:  Endocrinology       Date:  2004-04-29       Impact factor: 4.736

6.  Induction of hyperthyroidism in mice by intradermal immunization with DNA encoding the thyrotropin receptor.

Authors:  K Barrett; E Liakata; P V Rao; P F Watson; A P Weetman; P Lymberi; J P Banga; G Carayanniotis
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

7.  Schistosoma mansoni and alpha-galactosylceramide: prophylactic effect of Th1 Immune suppression in a mouse model of Graves' hyperthyroidism.

Authors:  Yuji Nagayama; Kanji Watanabe; Masami Niwa; Sandra M McLachlan; Basil Rapoport
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

8.  The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim.

Authors:  Chun-Rong Chen; Pavel Pichurin; Yuji Nagayama; Francesco Latrofa; Basil Rapoport; Sandra M McLachlan
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

9.  Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE).

Authors:  I A Ferber; S Brocke; C Taylor-Edwards; W Ridgway; C Dinisco; L Steinman; D Dalton; C G Fathman
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

10.  Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice.

Authors:  B Hultgren; X Huang; N Dybdal; T A Stewart
Journal:  Diabetes       Date:  1996-06       Impact factor: 9.461

View more
  8 in total

1.  Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity.

Authors:  Balaji B Ganesh; Palash Bhattacharya; Anupama Gopisetty; Bellur S Prabhakar
Journal:  J Interferon Cytokine Res       Date:  2011-08-08       Impact factor: 2.607

2.  Evidence that TSH Receptor A-Subunit Multimers, Not Monomers, Drive Antibody Affinity Maturation in Graves' Disease.

Authors:  Basil Rapoport; Holly A Aliesky; Chun-Rong Chen; Sandra M McLachlan
Journal:  J Clin Endocrinol Metab       Date:  2015-04-09       Impact factor: 5.958

3.  B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism.

Authors:  I Ueki; N Abiru; M Kobayashi; M Nakahara; T Ichikawa; K Eguchi; Y Nagayama
Journal:  Clin Exp Immunol       Date:  2011-01-14       Impact factor: 4.330

4.  The role and molecular mechanism of gut microbiota in Graves' orbitopathy.

Authors:  Y Li; B Luo; B Tong; Z Xie; J Cao; X Bai; Y Peng; Y Wu; W Wang; X Qi
Journal:  J Endocrinol Invest       Date:  2022-08-20       Impact factor: 5.467

Review 5.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

Review 6.  A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves' disease.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocrine       Date:  2019-09-27       Impact factor: 3.633

7.  Diosgenin relieves goiter via the inhibition of thyrocyte proliferation in a mouse model of Graves' disease.

Authors:  Hu Cai; Zhe Wang; Hai-qing Zhang; Fu-rong Wang; Chun-xiao Yu; Feng-xia Zhang; Ling Gao; Jian Zhang; Jia-jun Zhao
Journal:  Acta Pharmacol Sin       Date:  2013-11-18       Impact factor: 6.150

Review 8.  Infections and autoimmunity: a panorama.

Authors:  V Pordeus; M Szyper-Kravitz; R A Levy; N M Vaz; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.